Idera Pharmaceuticals to Present at the 3rd Annual Cancer Immunotherapy Conference

<0> Idera Pharmaceuticals, Inc.Lou Arcudi, 617-679-5517 </0>

Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing Toll-like receptor candidates for the treatment of autoimmune diseases and for use as vaccine adjuvants, today announced that members of the management team will be presenting at the third annual “Cancer Immunotherapy: A Long-Awaited Reality Conference” at the New York Academy of Medicine in New York City. The presentation will be made on Thursday, October 4, 2012 in Room 21 from 11:00 to 11:15 am.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has clinical development programs in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants. The Company is also advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit .

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.